185 related articles for article (PubMed ID: 27738808)
1. Population pharmacokinetics of Daunorubicin in adult patients with acute myeloid leukemia.
Varatharajan S; Panetta JC; Abraham A; Karathedath S; Mohanan E; Lakshmi KM; Arthur N; Srivastava VM; Nemani S; George B; Srivastava A; Mathews V; Balasubramanian P
Cancer Chemother Pharmacol; 2016 Nov; 78(5):1051-1058. PubMed ID: 27738808
[TBL] [Abstract][Full Text] [Related]
2. Carbonyl reductase 1 expression influences daunorubicin metabolism in acute myeloid leukemia.
Varatharajan S; Abraham A; Zhang W; Shaji RV; Ahmed R; Abraham A; George B; Srivastava A; Chandy M; Mathews V; Balasubramanian P
Eur J Clin Pharmacol; 2012 Dec; 68(12):1577-86. PubMed ID: 22562609
[TBL] [Abstract][Full Text] [Related]
3. Cellular pharmacokinetics of daunorubicin: relationships with the response to treatment in patients with acute myeloid leukemia.
Kokenberg E; Sonneveld P; Sizoo W; Hagenbeek A; Löwenberg B
J Clin Oncol; 1988 May; 6(5):802-12. PubMed ID: 3163363
[TBL] [Abstract][Full Text] [Related]
4. Daunorubicin metabolism in leukemic cells isolated from patients with acute myeloid leukemia.
Bogason A; Masquelier M; Lafolie P; Skogastierna C; Paul C; Gruber A; Vitols S
Drug Metab Lett; 2010 Dec; 4(4):228-32. PubMed ID: 20670211
[TBL] [Abstract][Full Text] [Related]
5. Daunorubicin pharmacokinetics and the correlation with P-glycoprotein and response in patients with acute leukaemia.
Galettis P; Boutagy J; Ma DD
Br J Cancer; 1994 Aug; 70(2):324-9. PubMed ID: 7914424
[TBL] [Abstract][Full Text] [Related]
6. P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia.
Tidefelt U; Liliemark J; Gruber A; Liliemark E; Sundman-Engberg B; Juliusson G; Stenke L; Elmhorn-Rosenborg A; Möllgård L; Lehman S; Xu D; Covelli A; Gustavsson B; Paul C
J Clin Oncol; 2000 May; 18(9):1837-44. PubMed ID: 10784624
[TBL] [Abstract][Full Text] [Related]
7. Role of daunorubicin in the induction therapy for adult acute myeloid leukemia.
Usui N; Dobashi N; Kobayashi T; Yano S; Maki N; Asai O; Saito T; Yamaguchi Y; Watanabe H; Kato A; Ogihara A; Katori M; Nagamine M; Takei Y; Yamazaki H; Funakoshi S; Tajima N; Ogawa M; Kuraishi Y
J Clin Oncol; 1998 Jun; 16(6):2086-92. PubMed ID: 9626208
[TBL] [Abstract][Full Text] [Related]
8. High-dose cytosine arabinoside and daunorubicin postremission therapy in adults with de novo acute myeloid leukemia. Long-term follow-up of a prospective multicenter trial.
Heil G; Mitrou PS; Hoelzer D; Freund M; Link H; Ehninger G; Steinke B; Ohl S; Wandt H; Fackler-Schwalbe E
Ann Hematol; 1995 Nov; 71(5):219-25. PubMed ID: 7492624
[TBL] [Abstract][Full Text] [Related]
9. Targeted inhibition of ULK1 enhances daunorubicin sensitivity in acute myeloid leukemia.
Qiu L; Zhou G; Cao S
Life Sci; 2020 Feb; 243():117234. PubMed ID: 31887299
[TBL] [Abstract][Full Text] [Related]
10. The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia.
Fassas A; Anagnostopoulos A
Leuk Lymphoma; 2005 Jun; 46(6):795-802. PubMed ID: 16019523
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia.
Dorr R; Karanes C; Spier C; Grogan T; Greer J; Moore J; Weinberger B; Schiller G; Pearce T; Litchman M; Dalton W; Roe D; List AF
J Clin Oncol; 2001 Mar; 19(6):1589-99. PubMed ID: 11250987
[TBL] [Abstract][Full Text] [Related]
12. [Relationship between pharmacokinetics and efficacy and toxicity of daunorubicin in children with acute leukemia].
Sun YN; Chai YH; Xu YJ; Lü H
Zhonghua Er Ke Za Zhi; 2009 Apr; 47(4):296-300. PubMed ID: 19555570
[TBL] [Abstract][Full Text] [Related]
13. High Doses of Daunorubicin during Induction Therapy of Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Prospective Clinical Trials.
Gong Q; Zhou L; Xu S; Li X; Zou Y; Chen J
PLoS One; 2015; 10(5):e0125612. PubMed ID: 25993000
[TBL] [Abstract][Full Text] [Related]
14. [The role of daunorubicin in induction therapy for adult acute myeloid leukemia].
Usui N; Dobashi N; Asai O; Yano S; Kato A; Osawa H; Uno S; Katori M; Nagamine M; Yahagi Y; Yamaguchi Y; Saito T; Kasama K; Takei Y; Ogihara A; Yamazaki H; Kobayashi T; Tajima N; Ogawa M; Kuraishi Y
Gan To Kagaku Ryoho; 2000 Jul; 27(8):1152-9. PubMed ID: 10945010
[TBL] [Abstract][Full Text] [Related]
15. Inverse relationship between leukaemic cell burden and plasma concentrations of daunorubicin in patients with acute myeloid leukaemia.
Bogason A; Quartino AL; Lafolie P; Masquelier M; Karlsson MO; Paul C; Gruber A; Vitols S
Br J Clin Pharmacol; 2011 Apr; 71(4):514-21. PubMed ID: 21204910
[TBL] [Abstract][Full Text] [Related]
16. Quantitative evaluation of intracellular uptake of daunorubicin in acute myeloid leukemia: a method analysis.
Kokenberg E; Sonneveld P; Nooter K; van der Steuyt K; Löwenberg B
Cancer Chemother Pharmacol; 1986; 17(1):63-8. PubMed ID: 3457648
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia.
Berman E; McBride M; Lin S; Menedez-Botet C; Tong W
Leukemia; 1995 Oct; 9(10):1631-7. PubMed ID: 7564501
[TBL] [Abstract][Full Text] [Related]
18. Higher plasma but not intracellular concentrations after infusion with liposomal daunorubicin compared with conventional daunorubicin in adult acute myeloid leukemia.
Löfgren C; Lehmann S; Jönsson-Videsäter K; Möllgård L; Linder O; Tidefelt U; Hassan M; Paul C
Ther Drug Monit; 2007 Oct; 29(5):626-31. PubMed ID: 17898654
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004.
Creutzig U; Zimmermann M; Bourquin JP; Dworzak MN; Fleischhack G; Graf N; Klingebiel T; Kremens B; Lehrnbecher T; von Neuhoff C; Ritter J; Sander A; Schrauder A; von Stackelberg A; Starý J; Reinhardt D
Blood; 2013 Jul; 122(1):37-43. PubMed ID: 23704089
[TBL] [Abstract][Full Text] [Related]
20. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study.
List AF; Kopecky KJ; Willman CL; Head DR; Persons DL; Slovak ML; Dorr R; Karanes C; Hynes HE; Doroshow JH; Shurafa M; Appelbaum FR
Blood; 2001 Dec; 98(12):3212-20. PubMed ID: 11719356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
